SAB BIO (SABS) Q3 2026 earnings review
SAB BIO fills two trial groups, but its costs double
SAB BIO closed the adult and teenage parts of its main diabetes trial while its spending climbed again. The Miami company sells nothing yet: SAB-142, its only drug, aims to protect the insulin-making cells of newly diagnosed type 1 diabetics. Operating costs reached $25.9 million, against $12.7 million a year earlier. Chief executive Samuel Reich said the study remains "on track to complete enrollment in the fourth quarter".
| Operating costs | $25.9 million $12.7 million a year ago |
|---|---|
| Loss excluding warrant accounting | $24.0 million $16.2 million a year ago |
| Cash and investments | $205.3 million $208.0 million three months earlier |
| Cash runway outlook | Unchanged through 2028, with enrollment finished this quarter |
⚖️ Verdict: 🟢 Bullish
The case got better. Enrollment, the nearest risk, now looks less likely to slip, and the FDA granted Fast Track status in October. One caution: shareholders own a smaller slice each quarter, because the share count rose 9% in three months and warrants tied to the trial's milestones will add plenty more.
The question now is whether the last children join before December 31. If they do, warrant holders can pay money in at fixed prices and the 2027 result keeps its date; if they do not, both slip together. The fourth-quarter report settles it.
🐂 Bull Case
Adult and Teenage Places Are Full
SAFEGUARD is the study that decides SAB BIO's future. It gives SAB-142, an antibody that aims to protect the insulin-making cells of the pancreas, to about 159 children and adults diagnosed with type 1 diabetes within the past few months.
In September the study's independent safety committee approved the last step down in age, "expanding enrollment to pediatric patients" aged five to eleven. The adult and adolescent groups are now "fully enrolled and closed for screening", and more than 60 sites across America, Europe and Australasia keep recruiting children.
Chief executive Samuel Reich said the study remains "on track to complete enrollment in the fourth quarter", and the release says enrollment "continued to accelerate" in the period. Chief medical officer Alexandra Kropotova said the committee cleared each step on schedule and saw "no new safety signal identified in the ongoing SAFEGUARD trial".
What to watch: the fourth-quarter statement, where SAB BIO can confirm that the last pediatric places filled before December 31. Full enrollment holds the second-half-2027 result on its date and ends the warrants whose exercise money funds the wait.
FDA Puts SAB-142 on Fast Track
In October the Food and Drug Administration granted SAB-142 Fast Track designation. The status is procedural: it exists to "expedite the review of therapies for serious conditions where there is an unmet medical need". Chief executive Samuel Reich also said it "does not change the FDA's standards for approval".
What the designation buys is access: more frequent meetings with reviewers, "eligibility for rolling review of the future BLA" and a chance at priority review. The regulatory route had already firmed in April, when the agency wrote that C-peptide, a blood marker of surviving insulin cells, may support accelerated approval.
What to watch: whether SAB BIO names a rolling submission plan before the 2027 result arrives. That would turn procedure into months saved, while silence leaves the designation as paperwork.
Positives this quarter didn't test
Three parts of the story got no test in these numbers. SAB BIO is building the means to make and sell a drug whose registrational result is still two years away, and the study that would widen its eventual use has not dosed anyone.
- Second farm: construction in progress reached $2.5 million, from $0.8 million at the end of last year, with no budget or opening date published.
- Emergent BioSolutions: the exclusive maker of SAB-142, on a "minimum aggregate spend of $36.0 million following approval".
- PRISE-hATG: seven sites planned, with the first patient expected this quarter.
- Redosing: Reich declined to say "how many patients have been redosed" so far.
What to watch: a priced Emergent commitment and a completion date for the farm, either of which would show how much cash the pre-launch build takes before a single sale.
🐻 Bear Case
Costs Doubled and the Cash Pile Shrank
SAB BIO sells nothing, so its quarterly report is a spending report, and the spending is still doubling. Finance chief Lucy To tied the research increase to clinical trial work and the staff behind it, and the administrative one to share-based pay.
- Research and development: $18.1 million, from $9.0 million a year earlier
- General and administrative: $7.8 million, from $3.7 million
- Share-based pay: $7.4 million, from $0.8 million, or 29% of all operating costs
- Costs excluding share-based pay: up 55% by our math
Cash tells a milder story, because share awards cost no money. By our math the quarter used about $13.7 million. Cash and investments slipped to $205.3 million, the second quarterly fall in a row, and that is after $13.4 million arrived from warrant exercises.
The company still promises an "operational runway through 2028". By our math that leaves nine quarters and allows about $23 million of cash use in each, so today's pace fits inside the promise with room to spare.
What to watch: the fourth-quarter cash figure and the first priced Emergent commitment. Spending near $14 million a quarter keeps the 2028 date without new money. A climb toward $23 million would make the promise rest on warrant holders paying in.
Shareholders Keep Paying For the Trial
Someone has to pay for a study that earns nothing, and at SAB BIO that someone is the shareholder. Common shares reached 91.1 million at the end of September, from 47.6 million at the end of last year, after March's share sale and a run of warrant exercises.
Behind the count sit about 140 million more common-equivalent shares in Series B warrants, which expire when enrollment finishes and when the data arrive. Their fixed prices, $1.75 and $2.19 per common share, make them the planned source of money for the wait. The option pool doubled this year, and SAB BIO has still to charge $87.4 million of that pay against future results.
This matters because a positive result in 2027 then divides across a far wider base. Warrants, options and preferred stock together came to 204.5 million potential shares at the end of September, more than twice the common shares outstanding.
What to watch: the share count in the next report and the warrant money beside it. The two tranches would raise $267 million if exercised in full, which would fund the study to its result and roughly double the count again.
Tzield Builds Its Lead Before SAB's Data
Tzield, an infusion that delays type 1 diabetes, is the approved drug in this field, and it now carries a licence in Stage 3, the stage SAB-142 targets. Chief executive Samuel Reich told analysts "we're very encouraged by what we're seeing with Tzield", and he reads its uptake as evidence that doctors will treat patients at diagnosis.
The reading cuts the other way too, because prescribing habits form early. SAFEGUARD does not report until the second half of 2027, and Reich's claim that SAB-142 is "a competitive product with fewer days of dosing" rests on no head-to-head study.
What to watch: the C-peptide result in 2027, together with the immunogenicity and redosing safety data Kropotova said will accompany it.
Risks this quarter didn't answer
Four standing risks got no answer this quarter, and none of them turns on the figures SAB BIO published. Each one needs a disclosure the company has not yet made.
- Enrollment deadline: children aged five to eleven are still joining, and only the fourth-quarter statement can confirm completion.
- Single asset: the registrational result lands in the second half of 2027, and today's efficacy evidence is four treated patients, with nothing collected past day 120.
- Supply: Emergent holds exclusive manufacturing rights for five years after approval, and the backup herd is still being built.
- Its own estimate: the warrant model used a "probability of survival" of 70% at September 30, against 40% at the end of last year.
What to watch: the annual report's clinical update, which should say whether all 159 patients joined and whether the second herd has started producing antibodies.
👓 Other Themes
Earnout Shares and Old Warrants Expired
After the quarter ended, a five-year clock from SAB BIO's 2021 listing ran out. The conditions for 1.2 million earnout shares went unmet, so the 1,049,194 shares held in escrow returned to the company as treasury stock. Old listing warrants, 595,860 in all, expired unused, and Nasdaq removed the public ones from listing in late October.
💲 Other KPIs
Total losses since the company began now stand at $174.6 million. The deficit has grown between 15% and 18% in each of the past four quarters, so the pace of loss-making is steady rather than climbing. Nothing in it unwinds until a product earns money.
Bills for trial work already received but not yet paid reached $5.1 million, against $0.3 million at the end of last year. Unpaid bills flatter the cash figure, so part of the spending this quarter leaves the account in a later one.
Earnings on the money raised keep climbing: $1.6 million this quarter against $0.6 million a year ago, as treasury holdings swelled after the March share sale and the warrant exercises. Interest now offsets about 6% of operating costs.
🔮 Guidance
Unchanged. Finance chief Lucy To repeated that $205.3 million funds operations through 2028. By our math that is nine quarters, allowing about $23 million of cash use in each; this quarter used roughly $14 million. The date has survived three statements while costs doubled, and SAB BIO still does not say whether warrant money sits inside it.
Unchanged. Reich said the study stays on course to take its last patient this quarter, with adults and adolescents closed and children aged five to eleven still joining. The date has stood since the first quarter, and it is also the event that ends the Enrollment Date warrants and converts them into cash.
Unchanged for a third quarter. The main measure — whether SAB-142 preserves insulin production, read as C-peptide area under the curve — arrives in the second half of 2027. Kropotova said blood-sugar control, immunogenicity and redosing safety will come with it. Every open question about the company waits on that date.
New. SAB BIO expects the investigator-led study in patients up to two years from diagnosis "to dose the first patient in Q4 this year", across seven planned sites. Reich said the budget already carried its cost, so the spending path does not change. He would not name a date for its results.
❓ Key Questions
Does the 2028 runway include warrant money?
SAB BIO repeats that $205.3 million funds operations through 2028. It has never said whether that assumes the $267 million its own trial milestones could pull in from warrant holders. The answer decides whether another share sale is coming.
How much will Emergent be paid, and when?
The filing promises "substantial payments to Emergent over the next 24 to 36 months", including production equipment, without a figure. Nobody outside the company can test the runway claim until management prices that commitment.
What does the second South Dakota farm cost?
Construction started in the second quarter to add capacity and a backup herd. Six months on there is no budget, no opening date and no stated effect on quarterly cash use.
How many patients received a second dose?
Redosing is the advantage SAB BIO claims over Tzield. Reich declined to say "how many patients have been redosed", so the central point of difference stays unmeasured in public until the 2027 data.
When will the second study report?
PRISE-hATG doses its first patient this quarter and could widen the eventual label to people two years from diagnosis. Reich would not name a date for its data, saying only that it follows SAFEGUARD.